Alzheimer’s Disease
A progressive disease that destroys memory and other important mental functions.
Brain cell connections and the cells themselves degenerate and die, eventually destroying memory and other important mental functions.
Memory loss and confusion are the main symptoms.
No cure exists, but medications and management strategies may temporarily improve symptoms.
Cluster Number:
Wiki Number: W007
Diagnosis: Alzheimer’s Disease
US Patients:
World Patients: 30Mil
Sex Ratio: M; 3F
Age Onset: 65+to42% by 80+
Brain Area: hippocampus, amyloids & tau proteins, 19 genes
Symptoms: forgetting, poor short term memory, location confusion
Progression: poor thinking, repetitious conversations, abusive, anxious, paranoid, loses ability to live
Causes: 19 genes, head injuries, depression, hypertension, smoking
Medications: memantine, acetylcholinemesterase inhibitors
Therapies: Chess, book-reading, exercise;low-fat diet, caffeine, wine
Youtube Video: Alzheimer’s Disease-Early Signs
Amazon or Library Book:
Is It Alzheimer’s?
Amazon or Library Book:
36-Hour Day
Click the book to link or order from Amazon.
Click the book to link or order from Amazon.
Support Group: Alzheimer’s Association 800-272-3900
Contact your local Social Security office for possible Disability Benefits through their Disability Determination Services,
Section 12.02.
4 CURRENT ARTICLES
FROM PUBMED
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- Comparative assessment of established and deep learning-based segmentation methods for hippocampal volume estimation in brain magnetic resonance imaging analysisby Hsi-Chun Wang on May 7, 2024
In this study, our objective was to assess the performance of two deep learning-based hippocampal segmentation methods, SynthSeg and TigerBx, which are readily available to the public. We contrasted their performance with that of two established techniques, FreeSurfer-Aseg and FSL-FIRST, using three-dimensional T1-weighted MRI scans (n = 1447) procured from public databases. Our evaluation focused on the accuracy and reproducibility of these tools in estimating hippocampal volume. The findings...
- Synaptic alterations associated with disrupted sensory encoding in a mouse model of tauopathyby Soraya Meftah on May 7, 2024
Synapse loss is currently the best biological correlate of cognitive decline in Alzheimer's disease and other tauopathies. Synapses seem to be highly vulnerable to tau-mediated disruption in neurodegenerative tauopathies. However, it is unclear how and when this leads to alterations in function related to the progression of tauopathy and neurodegeneration. We used the well-characterized rTg4510 mouse model of tauopathy at 5-6 months and 7-8 months of age, respectively, to study the functional...
- Assessment of Preanalytical Cerebrospinal Fluid Handling and Storage Factors on Measurement of Aβ1-42, Aβ1-40, and pTau181 Using an Automated Chemiluminescent Platformby Sara Ho on May 7, 2024
CONCLUSIONS: Storage of CSF at 4°C for 1 week or -80°C for 1 month did not significantly affect Aβ1-42, Aβ1-40, pTau181, or associated ratio measurements. Tube cap-contact impacted pTau181 and pTau181/Aβ1-42 values in larger tubes. Mixing methods are equivalent. The Aβ1-42/Aβ1-40 ratio compensates for freeze-thaw variability up to 4 cycles.
- An NMR Toolkit to Probe Amyloid Oligomer Inhibition in Neurodegenerative Diseases: From Ligand Screening to Dissecting Binding Topology and Mechanisms of Actionby Alessandro Palmioli on May 7, 2024
The aggregation of amyloid peptides and proteins into toxic oligomers is a hallmark of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Inhibition of amyloid oligomers formation and interactions with biological counterparts, as well as the triggering of non-toxic amorphous aggregates, are strategies towards preventive interventions against these pathologies. NMR spectroscopy addresses the need for structural characterization of amyloid proteins and their...